{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:41:31Z","timestamp":1790649691770,"version":"4.1.0"},"reference-count":9,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T00:00:00Z","timestamp":1398816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Head & Neck"],"published-print":{"date-parts":[[2015,6]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>The purpose of this study was to investigate the efficacy of bevacizumab (\u201cAvastin\u201d) for the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT).<\/jats:p><\/jats:sec>Methods<\/jats:title>In this double blind, placebo controlled trial, 15 adult patients with HHT with a minimum of 2 epistaxis episodes per week were randomized. A history of thromboembolic events or recent or planned surgery led to exclusion. Patients received a single intranasal submucosal injection (10 mL) of 100 mg bevacizumab or placebo. The primary outcome was the relative reduction of average daily epistaxis visual analog score (VAS).<\/jats:p><\/jats:sec>Results<\/jats:title>Average daily posttreatment VAS scores decreased by 27% in the bevacizumab group and by 3% in the placebo group (p<\/jats:italic> = .57). The reduction in HHT epistaxis severity scores was \u20100.61 greater in the bevacizumab group compared to the placebo group (p<\/jats:italic> = .34).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Results show a trend toward reduced epistaxis with bevacizumab. This further supports the use of bevacizumab in HHT. Clincial Trials. gov number: NCT01314274 \u00a9 2014 Wiley Periodicals, Inc. Head Neck<\/jats:italic> 37: 783\u2013787, 2015<\/jats:p><\/jats:sec>","DOI":"10.1002\/hed.23655","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T17:42:40Z","timestamp":1393954960000},"page":"783-787","source":"Crossref","is-referenced-by-count":68,"title":["Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double\u2010blind, randomized, placebo\u2010controlled trial"],"prefix":"10.1002","volume":"37","author":[{"given":"Dominik","family":"Riss","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Burian","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Krankenhaus der Barmherzigen Schwestern Linz Linz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Kranebitter","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kaider","sequence":"additional","affiliation":[{"name":"Center for Medical Statistics, Informatics and Intelligent Systems, Section of Clinical Biometrics Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Arnoldner","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P"},{"key":"e_1_2_7_3_1","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor\u2010beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick H","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0147-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20159"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.22501"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20818"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21415"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.23303"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21345"}],"container-title":["Head & Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.23655","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.23655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T02:17:02Z","timestamp":1696472222000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.23655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,30]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1002\/hed.23655"],"URL":"https:\/\/doi.org\/10.1002\/hed.23655","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,30]]}}}